Complete financial analysis of Wellnex Life Limited (WNX.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Wellnex Life Limited, a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- AXA SA (AXAHF) Income Statement Analysis – Financial Results
- SRF Limited (SRF.NS) Income Statement Analysis – Financial Results
- Cascade Acquisition Corp. (CAS) Income Statement Analysis – Financial Results
- Scalare Partners Holdings Limited (SCP.AX) Income Statement Analysis – Financial Results
- Flora Growth Corp. (FLGC) Income Statement Analysis – Financial Results
Wellnex Life Limited (WNX.AX)
About Wellnex Life Limited
Wellnex Life Limited develops health and wellness solutions in Australia. The company provides organic baby skincare products under the Little Innoscents; nutritional support products under the Performance Inspired; iron gummies under The Iron Company; organic milk under the Uganic; natural energy products under the Wakey Wakey; smooth textured capsules under the Liquigesic; and garlic products under the SupaGarlic brands. It also offers bin cleanser solutions under the Bin Buddy; medical products under the Bird Healthcare; gel plasters for treating blisters, corns, cracked heels, and cold sores under the Compeed; oral emergency contraception pills under the EllaOne; skincare solutions under the Koéna; canned meats under the Plumrose; snacks under the Simply7; skincare products under the edited; natural herbal skincare products under the naked klay; and natural essential oil blends under the Planet Remedy brands. In addition, the company provides contract manufacturing services. Wellnex Life Limited has a collaboration with Onelife Botanicals for the manufacture, distribution, and sales of cannabis and hemp-based products. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.93M | 27.88M | 18.61M | 1.20M | 1.05M | 887.00K | 1.44M | 928.43K | 9.98K | 1.51K | 455.01K |
| Cost of Revenue | 12.83M | 23.14M | 14.11M | 1.36M | 487.00K | 518.00K | 718.00K | 771.23K | 21.46K | 25.39K | 421.16K |
| Gross Profit | 4.11M | 4.74M | 4.50M | -165.00K | 561.00K | 369.00K | 723.00K | 157.20K | -11.48K | -23.89K | 33.85K |
| Gross Profit Ratio | 24.25% | 17.00% | 24.18% | -13.81% | 53.53% | 41.60% | 50.17% | 16.93% | -115.04% | -1,586.12% | 7.44% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.86M | 7.14M | 8.58M | 6.42M | 17.50M | 6.88M | 16.70M | 2.18M | 347.96K | 233.06K | 103.50K |
| Selling & Marketing | 2.89M | 4.43M | 1.67M | 1.98M | 3.27M | 2.37M | 3.75M | 1.03M | 20.47K | 0.00 | 0.00 |
| SG&A | 10.75M | 11.58M | 10.25M | 8.40M | 20.78M | 9.24M | 20.45M | 3.21M | 368.43K | 233.06K | 103.50K |
| Other Expenses | 0.00 | 16.00K | 186.00K | -9.48M | -4.80M | -1.55M | 83.00K | 11.28K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.07M | 11.85M | 10.37M | 8.53M | 30.15M | 9.34M | 20.46M | 4.08M | 368.43K | 206.13K | 108.72K |
| Cost & Expenses | 23.58M | 34.99M | 24.48M | 9.89M | 30.64M | 9.86M | 21.17M | 4.85M | 389.88K | 231.52K | 529.89K |
| Interest Income | 0.00 | 1.68M | 956.00K | 1.63M | 59.00K | 208.00K | 51.00K | 0.00 | 0.00 | 86.28K | 83.27K |
| Interest Expense | 2.40M | 1.68M | 956.00K | 1.63M | 860.00K | 25.00K | 40.00K | 185.73K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 774.00K | 274.00K | 147.00K | 83.00K | 226.00K | 11.00K | 8.00K | 41.00K | 7.84K | 7.84K | 5.08K |
| EBITDA | -10.57M | -11.89M | -6.35M | -18.41M | -64.36M | -10.22M | -19.79M | -3.92M | -372.06K | -256.95K | -69.65K |
| EBITDA Ratio | -62.43% | -24.48% | -29.90% | -1,512.72% | -2,796.09% | -1,151.75% | -1,359.47% | -416.84% | -3,728.80% | -17,061.75% | -15.31% |
| Operating Income | -6.64M | -7.10M | -5.68M | -18.17M | -29.53M | -10.32M | -19.60M | -3.91M | -379.90K | -264.79K | -74.73K |
| Operating Income Ratio | -39.23% | -25.46% | -30.54% | -1,520.33% | -2,817.65% | -1,163.02% | -1,360.03% | -421.23% | -3,807.38% | -17,582.40% | -16.42% |
| Total Other Income/Expenses | -7.10M | -6.73M | -1.55M | -10.83M | -35.91M | -1.28M | -107.00K | -240.14K | -163.52K | -51.50K | -83.41K |
| Income Before Tax | -13.74M | -13.85M | -7.45M | -20.40M | -58.94M | -10.34M | -19.84M | -4.15M | -535.59K | -316.29K | -158.14K |
| Income Before Tax Ratio | -81.14% | -49.67% | -40.03% | -1,706.78% | -5,624.33% | -1,165.84% | -1,376.75% | -447.09% | -5,367.67% | -21,002.06% | -34.76% |
| Income Tax Expense | 0.00 | 1.70M | 1.14M | -3.29M | -14.74M | -1.96M | 117.00K | 197.02K | -1.00 | 0.00 | 0.00 |
| Net Income | -13.74M | -13.85M | -7.45M | -24.69M | -46.27M | -9.91M | -19.83M | -4.15M | -535.59K | -316.29K | -158.14K |
| Net Income Ratio | -81.14% | -49.67% | -40.03% | -2,089.12% | -4,135.59% | -1,117.36% | -1,376.34% | -447.09% | -5,367.67% | -21,002.06% | -34.76% |
| EPS | -0.81 | -1.72 | -1.24 | -5.16 | -11.31 | -2.55 | -6.66 | -2.85 | -0.73 | -0.43 | -0.22 |
| EPS Diluted | -0.57 | -1.72 | -1.23 | -5.16 | -11.31 | -2.55 | -6.66 | -2.85 | -0.73 | -0.43 | -0.22 |
| Weighted Avg Shares Out | 17.01M | 8.07M | 6.03M | 4.79M | 4.09M | 3.89M | 2.98M | 1.46M | 734.26K | 734.26K | 734.26K |
| Weighted Avg Shares Out (Dil) | 23.90M | 8.07M | 6.03M | 4.79M | 4.09M | 3.89M | 2.98M | 1.46M | 734.26K | 734.26K | 734.26K |
Source: https://incomestatements.info
Category: Stock Reports
How has Wellnex Life’s revenue changed in FY24?
Revenue for FY24 of $16.9 million with 2HFY24 contributing $11.3 million with the acquisition of Pain Away. Margins for FY24 up 76% compared to FY23 from 17% to 30%, with margins in the 2HFY24 increasing to 40% compared to 11% in 1HFY24.
What impact did the acquisition of Pain Away have on Wellnex Life’s financials?
This transformational acquisition gives added impetu s to Wellnex Life’s financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.